Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N; Yin, Xiangfan; Kossenkov, Andrew V; Liu, Qin; Zhang, Gao; Krepler, Clemens; Cheng, Chaoran; Wei, Zhi; Somasundaram, Rajasekharan; Karakousis, Giorgos; Xu, Wei; Morrissette, Jennifer Jd; Lu, Yiling; Mills, Gordon B; Sullivan, Ryan J; Benchun, Miao; Frederick, Dennie T; Boland, Genevieve; Flaherty, Keith T; Weeraratna, Ashani T; Herlyn, Meenhard; Amaravadi, Ravi; Schuchter, Lynn M; Burd, Christin E; Aplin, Andrew E; Xu, Xiaowei; Villanueva, Jessie.
EMBO Mol Med
; 10(5)2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29650805
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Systemic treatments for metastatic cutaneous melanoma.
Novel Targeted Therapies for Metastatic Melanoma.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.